Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 103 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Atropin Clear all
Completed Phase 4 Interventional Results available

Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)

NCT03351608
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Sugammadex 2 mg/kg, Sugammadex 4 mg/kg, Neostigmine + Glycopyrrolate, Neostigmine + Atropine
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
2 Years to 16 Years
Enrollment
288 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • San Diego, California + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 5, 2021 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional

Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent® Inhalation Aerosol in COPD Patients.

NCT00388882
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, ipratropium bromide / albuterol
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
327 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
10
States / cities
Phoenix, Arizona • Lakewood, California • Sepulveda, California + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

The Influence of Atropine on Choroidal Thickness

NCT03158142
View directory record Official record
Conditions
Myopia
Interventions
Atropine Sulfate 1% Oph Soln
Drug
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
18 Years to 40 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Oct 30, 2026, 3:44 PM EDT
Recruiting Phase 4 Interventional

APPRAISE: Assessment of Pain and Posterior Synechiae Reduction With Atropine, an Investigation of Post-Surgical Eyes

NCT07434635
View directory record Official record
Conditions
Eye Disorders
Interventions
Atropine 1%
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 31, 2026 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 3 Interventional Results available

Combivent Respimat 1-year Safety Study in Patients With Chronic Obstructive Pulmonary Disease

NCT01019694
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Combivent CFC-MDI, Combivent Respimat 20/100 mcg, Atrovent HFA 42 mcg + Albuterol HFA 200 mcg
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
470 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
55
States / cities
Jasper, Alabama • Mobile, Alabama • Mesa, Arizona + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2014 · Synced Oct 30, 2026, 3:44 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Accommodation Behavior in Children Under Myopia Control Treatment (Pilot Study)

NCT04807361
View directory record Official record
Conditions
Accomodation, Biofeedback Training, Myopia
Interventions
Auditory biofeedback traing
Behavioral
Lead sponsor
State University of New York College of Optometry
Other
Eligibility
8 Years to 15 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Long Beach, New York
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 3 Interventional Results available

Trial Comparing Atropine to Atropine Plus a Plano Lens for the Sound Eye for Amblyopia in Children 3 to <7 Years Old

NCT00315302
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine, Plano Lens
Drug · Device
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 6 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
2
States / cities
Fullerton, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 19, 2016 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional Results available

A Trial Comparing Treatment With Tiotropium Inhalation Capsules to Combivent Inhalation Aerosol in COPD Patients.

NCT00359788
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
tiotropium, Combivent (Ipratropium/Albuterol)
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
40 Years and older
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
31
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional Results available

Effect of Nebulized Bronchodilators on Heart Rate

NCT01151579
View directory record Official record
Conditions
COPD, Sepsis, Shock
Interventions
Levalbuterol, Albuterol
Drug
Lead sponsor
Fahim Khorfan, MD
Industry
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Grand Blanc, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 23, 2015 · Synced Oct 30, 2026, 3:44 PM EDT
Not yet recruiting Phase 2 Interventional

Effect of Ipratropium Bromide on EILO

NCT07394036
View directory record Official record
Conditions
Exercise-Induced Laryngeal Obstruction, Dyspnea During Activity
Interventions
Ipratropium Bromide, Normal Saline (Placebo)
Drug
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
8 Years to 17 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Prosper, Texas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional

Trial Comparing Daily Atropine Versus Weekend Atropine

NCT00094614
View directory record Official record
Conditions
Amblyopia
Interventions
Atropine
Drug
Lead sponsor
Jaeb Center for Health Research
Other
Eligibility
3 Years to 7 Years
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 25, 2010 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
View directory record Official record
Conditions
Atropine Bioequivalence
Interventions
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Early Phase 1 Interventional

Pharmacokinetics of Atropine Oral Gel

NCT05164367
View directory record Official record
Conditions
Cerebral Palsy, Sialorrhea
Interventions
Atropine sulfate gel (0.01%)
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Dec 18, 2024 · Synced Oct 30, 2026, 3:44 PM EDT
Terminated Phase 4 Interventional Results available

Nebulizer Versus Dry Powdered Inhalers for Chronic Obstructive Pulmonary Disease (COPD)

NCT03219866
View directory record Official record
Conditions
COPD, COPD Exacerbation
Interventions
Nebulizers, Dry Powder Inhaler, Brovana, Pulmicort, Atrovent, Advair Diskus, Spiriva HandiHaler
Device · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2021 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual vs IV Atropine Bioavailability Study

NCT04290039
View directory record Official record
Conditions
Toxic Effect of Organophosphate and Carbamate Insecticides
Interventions
Atropine Sulfate Ophthalmic Solution, Atropine Sulphate Injection
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
High Point, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Early Phase 1 Interventional Results available

Defining and Treating Depression-related Asthma

NCT04617015
View directory record Official record
Conditions
Asthma, Depression, Childhood Asthma
Interventions
Ipratropium Bromide
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
7 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional

An Investigation of Topical Ophthalmic Low-Dose Atropine on Pupil Size and Accommodation

NCT07674966
View directory record Official record
Conditions
Myopia
Interventions
Atropine 0.01% Ophthalmic Solution, Atropine 0.02% Ophthalmic Solution, Atropine 0.05% Ophthalmic Solution
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 40 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dropless Pars Plana Vitrectomy Study

NCT05331664
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment
Interventions
Pars plana vitrectomy, Triamcinolone Acetonide 40mg/mL, Moxifloxacin 0.5% or Polymyxin/Trimethoprim if patient is allergic to moxifloxacin, Prednisolone 1%, Atropine 1%
Procedure · Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
40 Years and older
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 3 Interventional Results available

Study of Budesonide as an Addition to Standard Therapy in Adult Asthmatics in the Emergency Room.

NCT00588406
View directory record Official record
Conditions
Asthma
Interventions
Budesonide, albuterol, Ipratropium bromide, Prednisone
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 60 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
3
States / cities
East Meadow, New York • Queens, New York • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jan 21, 2016 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 1 Interventional

The Pathophysiology of Orthostatic Hypotension

NCT00748059
View directory record Official record
Conditions
Autonomic Nervous System Diseases, Orthostatic Hypotension, Dopamine Beta-Hydroxylase Deficiency, Orthostatic Intolerance
Interventions
Standing or upright tilt, Microneurography, QSweat, neck cuff stimulation, phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine, clonidine,yohimbine,metoclopramide,alpha-methyldopa, BodPod, Eye exam, Sleep study, Pain response testing, Metabolic chamber, Brain function studies, Bicycle Exercise Test
Procedure · Device · Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
12 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2020
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional Results available

Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly

NCT01951118
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Delirium, Dementia, Amnestic, Cognitive Disorders
Interventions
Donepezil
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
55 Years to 95 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 4 Interventional Results available

A Pilot Study to Determine the Feasibility and Utility of Implementing of the Full Scale TOM Trial

NCT01696214
View directory record Official record
Conditions
Asthma
Interventions
Fluticasone 250 mg/salmeterol 50 mg, Montelukast 10mg, Theophylline 400 mg, ipratropium
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2019 · Synced Oct 30, 2026, 3:44 PM EDT
Terminated Phase 2 Interventional Results available

Sacituzumab Govitecan for Relapsed Ovarian, Endometrial, and Cervical Carcinomas

NCT06865677
View directory record Official record
Conditions
Recurrent Platinum Resistant Epithelial Ovarian Carcinoma, Recurrent Epithelial Endometrial Carcinoma, Recurrent Epithelial Cervical Carcinoma
Interventions
Sacituzumab Govitecan, EKG, Brain MRI, CT scans, Tumor biopsy, Loperamide, Octreotide, Diphenoxylate/Atropine, Antiemetics
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 30, 2026, 3:44 PM EDT
Completed Phase 2 Interventional Results available

PT001 MDI Versus Atrovent Study in Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

NCT01350128
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease
Interventions
PT001 MDI, Ipratropium Bromide HFA Inhalation Aerosol, Placebo MDI
Drug · Other
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Eligibility
40 Years to 80 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
8
States / cities
Panama City, Florida • Winter Park, Florida • Cherry Hill, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2018 · Synced Oct 30, 2026, 3:44 PM EDT